Progenra, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Progenra, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Progenra, Inc. - Product Pipeline Review - 2014', provides an overview of the Progenra, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenra, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Progenra, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Progenra, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Progenra, Inc.'s pipeline products

Reasons to buy

- Evaluate Progenra, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Progenra, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Progenra, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Progenra, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenra, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Progenra, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Progenra, Inc. Snapshot 4
Progenra, Inc. Overview 4
Key Information 4
Key Facts 4
Progenra, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Progenra, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Progenra, Inc. - Pipeline Products Glance 9
Progenra, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Progenra, Inc. - Drug Profiles 11
P-005091 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Small Molecules for Cancer 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Small Molecules to Inhibit IDOL for Hypercholesterolemia 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Small Molecules to Inhibit Synoviolin/Hrd 1 for Rheumatoid Arthritis 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecules to Inhibit USP8 for Cystic Fibrosis 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Progenra, Inc. - Pipeline Analysis 17
Progenra, Inc. - Pipeline Products by Molecule Type 17
Progenra, Inc. - Recent Pipeline Updates 18
Progenra, Inc. - Dormant Projects 19
Progenra, Inc. - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables
Progenra, Inc., Key Information 4
Progenra, Inc., Key Facts 4
Progenra, Inc. - Pipeline by Indication, 2014 6
Progenra, Inc. - Pipeline by Stage of Development, 2014 7
Progenra, Inc. - Monotherapy Products in Pipeline, 2014 8
Progenra, Inc. - Preclinical, 2014 9
Progenra, Inc. - Discovery, 2014 10
Progenra, Inc. - Pipeline by Molecule Type, 2014 17
Progenra, Inc. - Recent Pipeline Updates, 2014 18
Progenra, Inc. - Dormant Developmental Projects,2014 19